What is the purpose of the Bridge Credit Agreement?

The Bridge Credit Agreement is a €9.25 billion financing facility designed to provide Thermo Fisher Scientific Inc. with the necessary funds to complete its acquisition of QIAGEN N.V. The funds will be used to purchase QIAGEN's equity securities as part of the public tender offer and to cover associated transaction expenses.

What are the key terms of the bridge loan facility?

The facility is a 364-day senior unsecured bridge loan. It has a principal amount of up to €9.25 billion and will bear interest at rates that vary based on Thermo Fisher's debt ratings. The agreement also includes specific fees and financial covenants that Thermo Fisher must adhere to.

When can Thermo Fisher access the funds from the bridge loan?

The funds can be drawn in up to two installments. The first drawing is contingent upon the successful completion of the tender offer for QIAGEN shares, where Thermo Fisher accepts tendered equity interests and payment is made. A second drawing may be made up to 120 days after the closing date of the acquisition.

What are the financial obligations Thermo Fisher must meet under this agreement?

Thermo Fisher must maintain certain financial ratios. Specifically, it needs to keep its consolidated indebtedness to consolidated EBITDA ratio at or below 4.5:1.0 (stepping down to 4.0:1.0 and then 3.5:1.0 over time) and a consolidated interest coverage ratio of at least 3.0:1.0. These ratios are subject to adjustments for certain qualified acquisitions.

TMO 8-K: Material Agreements & Financial Events

Summary

Thermo Fisher Scientific Inc. (TMO) has filed an 8-K detailing the execution of a Bridge Credit Agreement on April 17, 2020, related to their previously announced acquisition of QIAGEN N.V. This agreement provides a 364-day senior unsecured bridge loan facility of up to €9.25 billion. The primary purpose of this facility is to fund the cash portion of the QIAGEN acquisition, including the purchase of outstanding equity securities at €39 per share, and to cover associated transaction costs. This financing is crucial for Thermo Fisher to complete its strategic acquisition of QIAGEN. The financing terms include specific conditions for drawing the funds, interest rates that vary based on Thermo Fisher's debt ratings, and various fees such as ticking, funding, and duration fees. The agreement also imposes financial covenants on Thermo Fisher, including maintaining a consolidated indebtedness to consolidated EBITDA ratio and a consolidated interest coverage ratio. Investors should note the scale of the financing and the associated covenants, which are designed to ensure Thermo Fisher's financial health throughout the acquisition process.

Key Highlights

1Thermo Fisher entered into a €9.25 billion, 364-day senior unsecured bridge loan facility on April 17, 2020.
2The bridge loan is specifically intended to fund the cash acquisition of QIAGEN N.V. at €39 per share and related costs.
3The facility allows for up to two drawings, with the first tied to the successful tender offer completion for QIAGEN shares.
4Interest rates on the loans will be based on the EURIBO Rate or Base Rate plus a margin, varying with Thermo Fisher's debt ratings.
5Thermo Fisher will incur various fees, including ticking fees, a funding fee of 0.50%, and duration fees.
6The agreement includes financial covenants requiring maintenance of specific consolidated indebtedness to EBITDA and interest coverage ratios.
7The bridge loan facility is a material definitive agreement in connection with the QIAGEN acquisition, previously announced on March 3, 2020.

THERMO FISHER SCIENTIFIC INC. 8-K Report, Material Agreement (Apr 23, 2020)

Summary

Key Highlights

Frequently Asked Questions